background: The higher prevalence of preterm birth (PTB) and low birthweight (LBW) following infertility treatment may relate to the treatment itself or indicate that subfertility predisposes to a higher risk. Our aim was to examine whether basal FSH levels are related to the risk for PTB and LBW among pregnancies resulting from IVF.
Introduction
Pregnancies resulting from infertility treatments have been associated with an increased risk of preterm birth (PTB) and low birthweight (LBW), even among singleton gestations (Tanbo et al., 1995; Addor et al., 1998; Perri et al., 2001; Helmerhorst et al., 2004; Jackson et al., 2004; McGovern et al., 2004; Schieve et al., 2004; Wang et al., 2005) . The higher prevalence of these morbidities may relate to treatment, or indicate that subfertility predisposes to a higher risk for PTB and LBW. Whereas the prevalence of PTB and LBW is increased among women receiving treatment for subfertility (other than IVF), it also increased in untreated women having a prolonged time-to-pregnancy, suggesting that there may be factors that both decrease reproductive efficiency and increase the risk for adverse pregnancy outcomes, such as PTB and LBW (Joffe and Li, 1994; Basso and Baird, 2003; Axmon and Hagmar, 2005; Zhu et al., 2007; Allen et al., 2008; Romundstad et al., 2008) .
Decreased oocyte quality is one factor that could lower cycle fecundity and also predispose to increased risks for PTB and LBW, via mechanisms operating during early embryonic development. Placental pathology-manifested by abruption, gestational diabetes and pre-eclampsia-is also associated with growth restriction and premature birth (Meekins, 1994; Walker, 2000; Sibai et al., 2005; Norwitz, 2006; Van der Steeg et al., 2007) .
Oocyte quality can be assessed only indirectly via surrogate measures, which include age and serum markers of 'ovarian reserve'. Reproductive aging is associated with a decline in both the quantity (reserve) and the quality of the oocyte pool. As the overall number of oocytes declines, the number of follicles that can be recruited in each cycle decreases. Accordingly, the likelihood for ovulating a poor quality oocyte may increase, as selection and discrimination become more limited (Steiner, 2009) . The most commonly used and thoroughly studied serum marker of ovarian reserve is the FSH concentration; both basal (Cycle Day 2-4) and stimulated values (Day 10, after treatment with clomiphene citrate on Cycle Days 5 -9) predict oocyte yield (relating to oocyte quantity) and, to a lesser extent, IVF outcomes (reflecting oocyte quality; Muasher et al., 1988; Toner et al., 1991; Sharif et al., 1998; Jain et al., 2004) .
The relationship between ovarian reserve and perinatal morbidity in infants resulting from IVF has not been explored previously. We examined the association between the maximum basal or clomiphene-stimulated serum FSH levels and the prevalence of PTB and LBW in a large cohort of women who conceived via IVF. We hypothesized that higher FSH levels would be associated with increased rates of PTB and LBW.
Materials and Methods
Our retrospective cohort study was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill (NC, USA). We analyzed data from the 2008 Society for Assisted Reproductive Technology (SART) database of IVF outcomes, which includes patient data from 85% of treatment centers in the USA (SART, 2010) . Clinics report patient characteristics, treatment regimens and cycle outcomes for each IVF cycle. Our analysis included all women who underwent a fresh nondonor IVF cycle in 2008 that resulted in a singleton live birth (n ¼ 18 866). Women who received gamete intra-fallopian transfer (n ¼ 7) were excluded, but the few who received zygote intra-fallopian transfer (n ¼ 5) were included.
We further restricted our analysis to women with a recorded 'maximum historical FSH value' (n ¼ 14 262), which excluded 24% of the total population. The 'maximum historical FSH value' in the SART database is the patient's highest recorded FSH value obtained on Cycle Day 2, 3 or 4 of the menstrual cycle or on Cycle Day 10 after treatment with clomiphene citrate 100 mg daily, on Cycle Days 5 -9 (clomiphene citrate challenge test, CCCT). This is the value for the highest early follicular phase FSH value (or Day 10 following CCCT) ever recorded for the patient, which may or may not correspond to the particular singleton gestation studied here. The maximum FSH value is thought to more appropriately describe overall ovarian reserve. Those having a recorded FSH value tended to be older (34.2 + 4.2 versus 33.3 + 4.3 years, P , 0.001), were less likely to be nulligravid (48 versus 50%, P ¼ 0.03) or to have had a blastocyst transfer (30 versus 35%, P , 0.001), and had a lower BMI (24.9 + 5.4 versus 25.2 + 5.8 kg/m 2 , P ¼ 0.03). Birthweight and gestational age at delivery in women with and without a recorded maximum serum FSH level did not differ.
Our analysis included 14 086 women, after excluding women for whom no information on infant gestational age at delivery (n ¼ 64) or infant birthweight (n ¼ 112) was available.
Outcome definitions
The primary outcomes for our analysis were infant gestational age at delivery, PTB, birthweight, LBW and LBW at term. Gestational age at delivery was calculated as date of delivery minus the date of transfer, plus 14 days, plus the day of transfer (Day 2, 3, 4, 5, 6 or 7 after fertilization).
A gestational age ,259 days (37 weeks) was defined as a PTB. Gestational ages ,140 days (20 weeks) were not considered live births and were not included in the analysis. LBW was defined as a birthweight ,2500 g. For analysis of LBW at term, only term deliveries were analyzed.
Exposure and covariate assessment
The primary 'exposure' was the recorded maximum FSH value (mIU/ml) recorded prior to the cycle in which the patient conceived. Other collected information included age at start of the IVF cycle, gravidity, parity, number of previous PTBs, weight, height, smoking status, ethnicity, infant gender and use of assisted hatching.
Statistical analyses
All statistical analyses were conducted using STATA 10.0 (STATA, College Station, TX, USA). Bivariate analyses were conducted to determine the most appropriate method for modeling continuous and categorical covariates and to identify potential confounders. In subsequent analyses, serum FSH values were categorized into quartiles and modeled as an ordinal variable; the middle two quartiles were collapsed into one group, resulting in a total of three groups (defined by FSH levels of 1-5, 6-8 and ≥9 mIU/ml). Two linear regression models examined the relationship between FSH and gestational age and between FSH and birthweight. Three log linear binomial regression models determined risk ratios for the relationships between FSH and PTB, FSH and LBW, and FSH and LBW at term. Covariates considered as potential confounders (based on bivariate analysis) were included in the models. Assuming 9% of singletons would be LBW and 15% of singletons births would be preterm, and considering the women in the upper quartile of FSH as 'exposed' and the lower three quartiles as 'unexposed', the study had sufficient power (80% or higher) to detect a risk ratio of 1.1 for PTB and 1.3 for LBW.
Additional analyses were performed to determine whether treatment decisions (assisted hatching, blastocyst transfer) were related to FSH levels or associated with differing rates of PTB and LBW. Subgroup analyses divided the group by type of transfer (blastocyst versus cleavage stage) and examined the rates of PTB and LBW by FSH quartile within these two groups.
Statistical significance was set at P , 0.05.
Results
Women in the cohort (n ¼ 14 086) had an average age of 34 + 4.2 years, and were predominantly white (76%) and nulliparous (72%). Approximately one-half (48%) were nulligravid and 3% had a previous PTB. The majority (58%) had a normal BMI (mean 25 + 5.4 kg/m 2 ) and 6% were categorized as smokers. The average maximum recorded FSH value was 7.4 + 2.9 mIU/ml; 18% of women in the cohort had an FSH value ≥10 mIU/ml. The average gestational age at delivery was 270 + 16 days and 13% of women had a PTB. The average birthweight was 3227 + 616 g and 10% of women delivered a LBW infant. Among term infants, 3% had LBW.
Significantly lower mean birthweights were observed in younger women, with the lowest mean birthweight (3188 + 617 g) in women ,30 (Table I ). The risk of PTB and LBW differed significantly by ethnicity; black women had the highest rates of PTB (23%) and LBW (19%), and also the lowest mean gestational age (266 + 24 days) and birthweight (2968 + 739 g). The risk of PTB was highest (18%) among women with the highest BMI (.40 kg/m 2 ) and among women with a previous PTB (23%). The risk of PTB tended to be higher 
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(this was not significant) among smokers (16 versus 13% in nonsmokers). Male fetal gender was associated with lower gestational age and mean birthweight and significantly higher rates of PTB and LBW. As FSH levels increased, the gestational age at delivery increased significantly (Table II) and the risk of PTB decreased significantly (Table III) . The IVF offspring of women in the highest quartile of FSH levels (≥9 mIU/ml) had the longest adjusted mean gestational age (271.2 days) and the lowest adjusted relative risk (RR) of PTB [0.87, 95% confidence interval (CI): 0.76 -1.01] when compared with women in the lowest quartile of FSH levels (1-5 mIU/ml) who had the shortest adjusted mean gestational age (269.7 days).
Infant birthweight increased significantly (Table II) and risk for a LBW infant decreased (Table III) as the FSH concentration increased. Women in the highest quartile of FSH levels (≥9 mIU/ml) delivered infants with the highest adjusted mean birthweight (3249 g) and the lowest adjusted RR of LBW (0.89, 95% CI: 0.73 -1.04) when compared with women in the lowest quartile of FSH levels (1 -5 mIU/ml) who delivered infants with the lowest adjusted mean birthweight (3213 g). The risk for the term LBW was not associated with FSH concentrations (Table III) .
To further clarify the relationship between FSH levels and infant birthweight, we analyzed the prevalence of small for gestational age (SGA) infants by FSH level. SGA was defined as birthweight ,10% of expected for gestational week (Alexander et al., 1996) . The risk of SGA did not differ by quartile of FSH level in unadjusted analyses or after adjusting for age, ethnicity, BMI, nulliparity, smoking status, history of PTB and infant gender (relative risk ¼ 0.95, 95% CI: 0.80 -1.12, for women with FSH ≥ 9, compared with women with FSH 1-5 mIU/ml). We also examined the effect of cycle medication requirements [total dose of recombinant FSH (rFSH)] on perinatal outcomes. We found that women with LBW offspring required less rFSH than women without LBW infants (3043 + 1605 versus 3127 + 1593 IU, P ¼ 0.07) and that women with PTB offspring required less rFSH (3053 + 1600 versus 3129 + 1599 IU, P ¼ 0.06). Adjusting for total dose of rFSH did not alter the associations found previously between FSH values and LBW, or FSH values and PTB.
In a separate analysis, we examined the relationship between FSH values and PTB in groups with endometriosis (n ¼ 1764) and without endometriosis (n ¼ 12 322). The relationship between FSH and PTB persisted in those patients without endometriosis (FSH . 9 versus FSH , 6, RR 0.79, 95% CI: 0.69 -0.90) but not in those patients with endometriosis (FSH . 9 versus FSH , 6, RR 1.01, 95% CI: 0.72 -1.42).
To determine whether treatments such as blastocyst culture or assisted hatching contribute to the excess risk of LBW and PTB among births resulting from assisted reproduction technologies, we analyzed the rates of blastocyst transfer and assisted hatching by FSH level. Women in the lowest FSH quartile were significantly more likely to have had a blastocyst transfer than women in the highest FSH quartile (33 versus 24% increased risk for PTB (14 versus 12.6%, P ¼ 0.03); blastocyst transfer was not associated with risk for LBW (10.2 versus 9.6%, P ¼ 0.28). Assisted hatching was not associated with either PTB or LBW. In a subgroup analysis by transfer type (cleavage stage versus blastocyst), the association between FSH and PTB and LBW persisted in both groups (Table IV) . The offspring of women in the highest quartile of FSH levels again demonstrated the lowest rates of PTB and LBW in both the cleavage stage and blastocyst transfer groups, with data in the cleavage stage transfer group reaching statistical significance.
Discussion
Contrary to our hypothesis, women with the lowest ovarian reserve, as suggested by their higher serum FSH levels, did not exhibit the highest rates of PTB or LBW in singleton births resulting from IVF. In fact, women in the highest quartile of FSH levels had the lowest rates of these adverse outcomes. We also did not observe any association between term LBW and serum FSH concentrations.
Our findings suggest that declining ovarian reserve and, by inference, oocyte quality, do not predispose to an increased risk for PTB. Notably, the absolute difference between the adjusted mean gestational age for the lowest (269.7 days) and highest quartiles of FSH levels (271.2 days) was only 1.5 days, a difference having no clinical significance at a gestational age .38 weeks. After adjusting for confounders, higher FSH levels resulted in only a 13% reduction in the risk of PTB. Whereas higher serum FSH levels have minimal 'protective effect', they also do not appear to adversely affect pregnancy outcomes.
Our data suggest that the increased incidence of PTB observed in IVF pregnancies does not reflect a declining ovarian reserve and must be attributed to another independent oocyte factor or other factors present in a subfertile population relating to the uterus, tubal/peritoneal disease or some element of treatment. Perri et al. (2001) observed an overall significantly higher prevalence of PTB in IVF pregnancies (20%), compared with naturally conceived pregnancies (4%) but not in a subgroup of patients with 'pure' male factor infertility treated with ICSI (4.5%), suggesting a link between 'female' factors and PTB. A retrospective review of Australian national birth data observed a similar association (Wang et al., 2005) . Women with endometriosis have demonstrated higher rates of PTB, regardless of how they conceived (Stephansson et al., 2009) . Our findings regarding PTB persisted in women without endometriosis; however, in women with endometriosis, the risk of PTB was approximately equal for all quartiles of FSH values. Chung et al. (2006) reported increased rates of perinatal morbidity (PTB, LBW, fetal death) in IVF pregnancies after controlling for multiple gestations. They found no associations between perinatal morbidity and poor oocyte quality, cause of infertility, medication type or embryo manipulation but did observe an association with poor endometrial development, leading them to suggest that disorders of placentation predisposing to PTB and LBW might result from endometrial dysfunction rather than from abnormal trophoblast signaling. Our analysis found that as serum FSH concentrations rose, mean birthweight increased and the RR of LBW declined. As with the differences observed in the rates of PTB, the absolute difference between the adjusted mean birthweight for the lowest (3213 g) and the highest quartile of FSH levels (3249 g) was small ((36 g) and likely of no clinical importance at weights above 3200 g (7 pounds). We observed no association between term LBW or SGA and FSH levels, suggesting that the modest protective effect of higher FSH levels on risk for LBW can be attributed to longer gestations and lower rates of PTB.
Perinatal morbidities following IVF may be iatrogenic. Higher rates of morbidity following fresh (versus frozen) embryo transfers may reflect the adverse impact of grossly elevated concentrations of estradiol (E 2 ) and progesterone that result from exogenous gonadotrophin stimulation during an IVF cycle, particularly in women who develop ovarian hyperstimulation syndrome (Perri et al., 2001; Wang et al., 2005; Chung et al., 2006; Henningsen et al., 2010; Kansal Kalra et al., 2010) . In contrast, because women with higher serum FSH concentrations generally achieve lower peak serum E 2 levels after stimulation, their endometrium may escape such extreme supraphysiologic steroid hormone levels at the time of embryo transfer. We performed a preliminary analysis of our data, using the number of oocytes retrieved as a surrogate for ovarian hyperstimulation, and found that risks of both LBW and PTB increased with the number of oocytes retrieved (data not shown). The relationship between ovarian hyperstimulation and perinatal morbidity in IVF cycles merits further study. It also may be informative to examine the prevalence of PTB and LBW in pregnancies resulting from frozen embryo transfer cycles among women with different FSH levels. Such an analysis would effectively eliminate the influence of supraphysiological estrogen levels at the time of transfer (because serum E 2 levels in frozen embryo transfer cycles generally remain within the physiological range) but not at the time of fertilization/embryo creation (at or near the time when stimulated E 2 levels peak in fresh IVF cycles).
Originally, our study was designed to examine the effect of patient characteristics on perinatal morbidities. However, after finding associations that did not support our hypothesis, we investigated whether treatment decisions, presumably based on patient characteristics, could explain our observations. In our study, women with lower FSH values did have a higher rate of blastocyst transfer, and blastocyst transfer was significantly associated with increased risk for PTB, as also observed by Kallen et al. (2010) . However, the higher prevalence of blastocyst transfer among women with lower FSH values did not explain their higher risk for PTB; both PTB and LBW also were more prevalent among women with lower FSH values who received a cleavage stage embryo.
Our study employed a large national database to address a novel question regarding the association between an accepted marker of ovarian reserve (FSH) and perinatal morbidities observed among births resulting from IVF. The SART database contains a large body of information about each woman who received treatment, which permits adjustment for a number of potential confounders. Notably, 4597 patients (24%) were excluded from the cohort for the lack of a recorded maximum FSH value but those excluded also were younger, more likely to be nulligravid and more likely to have a blastocyst transfer, all suggesting that they were more likely to have FSH values in the lower quartiles. Nonetheless, exclusion of the group of women having no recorded FSH value may represent a possible selection bias and could make the results of our study difficult to extrapolate to other populations.
Our population was similar to previously reported populations in that young age, African-American race, obesity, smoking, male fetal gender and prior PTB were associated with increased risks of PTB and LBW (McGregor et al., 1992; Slattery and Morrison, 2002; Wang et al., 2010; York et al., 2010) .
Our study may be limited by our measure of ovarian reserve. The serum FSH concentrations reported to SART have never been validated, there is potential for data entry errors and assay methodology may vary significantly between centers. It was not possible to discern or distinguish between basal and clomiphene-stimulated FSH values but the two have the same use, interpretation and clinical implications. Finally, the serum FSH concentration is only an indirect measure of the number and, by inference, the quality of the remaining oocyte pool. The FSH level is a reasonably good predictor of response to stimulation (reflecting the number of remaining oocytes and the size of the recruitable cohort) in IVF cycles but predicts pregnancy (reflecting oocyte quality) with significantly less accuracy (Muasher et al., 1988; Toner et al., 1991; Sharif et al., 1998; Toner, 2003; Jain et al., 2004) . However, women having a 'reduced ovarian complement' (related to congenital absence or ovarian surgery) are at an increased risk for conceiving an aneuploid pregnancy, suggesting that ovarian reserve and oocyte quality are linked, and numerous studies have observed that higher FSH levels are associated with an increased incidence of aneuploidy, independent of maternal age (Nasseri et al., 1999; van Montfrans et al., 1999; Freeman et al., 2000) .
Although the observed decrease in gestational age at birth and increase in PTB in women with low FSH values have little clinical significance, the lack of an association between diminished ovarian reserve and poor perinatal outcomes is surprising and the information is valuable for patient counseling. Our study does not suggest that ovarian reserve, as reflected by the peak basal or clomiphenestimulated FSH levels, is the primary mediator of PTB and LBW in singleton IVF pregnancies. Rather, our results suggest that the increased prevalence of perinatal morbidities observed among pregnancies resulting from IVF result from other factors that remain to be defined. Future research should seek to identify these other factors and should adjust for basal FSH values when considering these perinatal outcomes.
